Teladoc (TDOC) Announces First Quarter Loss, Delays Revenue Estimates


Jeladoc (TDOC) exited with a quarterly loss of $0.47 per share against Zacks consensus estimate of a loss of $0.55. That compares to earnings of $0.13 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of 14.55%. A quarter ago, this telehealth service provider was expected to post a loss of $0.59 per share when it actually produced a loss of $0.07, delivering a surprise 88 .14%.

In the past four quarters, the company has exceeded consensus EPS estimates three times.

Teladoc, which is part of Zacks’ medical services business, posted revenue of $565.35 million for the quarter ended March 2022, missing Zacks’ consensus estimate by 0.63%. That compares to revenues of $453.68 million a year ago. The company has exceeded consensus revenue estimates three times in the past four quarters.

The sustainability of the immediate stock price movement based on recently released numbers and future earnings forecasts will primarily depend on management’s comments on the earnings call.

Teladoc stock has lost about 37.1% since the start of the year compared to a decline of -12.4% for the S&P 500.

What’s next for Teladoc?

While Teladoc has underperformed the market so far this year, the question on investors’ minds is: what’s next for the stock?

There is no easy answer to this key question, but a reliable measure that can help investors answer it is the company’s earnings outlook. This includes not only current consensus earnings expectations for the upcoming quarter(s), but also how those expectations have changed recently.

Empirical research shows a strong correlation between short-term stock movements and trends in earnings estimate revisions. Investors can track these revisions on their own or rely on a proven scoring tool like Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Upstream of this publication of the results, the trend of the revisions of estimates for Teladoc: favorable. While the magnitude and direction of estimate revisions may change following the release of the company’s earnings report, the current situation results in a Zacks No. 2 (buy) ranking for the stock. Thus, stocks are expected to outperform the market in the near future. You can see the full list of today’s Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how the estimates for the next few quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.45 on $614.21 million in revenue for the upcoming quarter and -$1.55 on $2.59 billion in revenue for the current fiscal year .

Investors should be aware that the outlook for the sector can also have a significant impact on stock performance. In terms of Zacks industry rankings, medical services currently sits in the bottom 15% of over 250 Zacks industries. Our research shows that the top 50% of industries ranked by Zacks outperform the bottom 50% by a factor of more than 2 to 1.

Avantor, Inc. (AVTR), another stock in the same sector, has yet to report results for the quarter ending March 2022. The results are expected to be released on April 28.

This company is expected to post quarterly earnings of $0.35 per share in its next report, which is no change from the year-ago quarter. The consensus EPS estimate for the quarter remained unchanged for the past 30 days.

Avantor, Inc.’s revenue is expected to be $1.93 billion, up 8.2% from the year-ago quarter.

Zacks names ‘only one best choice for doubling up’

From thousands of stocks, 5 Zacks experts have each picked their favorite to skyrocket by +100% or more in the coming months. Of these 5, Research Director Sheraz Mian selects one to have the most explosive advantage of all.

It’s a little-known chemical company that’s up 65% year-on-year, but still very cheap. With relentless demand, rising earnings estimates for 2022 and $1.5 billion for stock buybacks, retail investors could jump in at any moment.

This company could rival or surpass other recent Zacks stocks which are expected to double, such as Boston Beer Company which jumped +143.0% in just over 9 months and NVIDIA which jumped +175.9% in one. year.

Free: See our best stock and our 4 finalists >>

Click to get this free report

Teladoc Health, Inc. (TDOC): Free Stock Analysis Report

Avantor, Inc. (AVTR): Free Stock Analysis Report

To read this article on Zacks.com, click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


nasdaq

Not all news on the site expresses the point of view of the site, but we transmit this news automatically and translate it through programmatic technology on the site and not from a human editor.
Back to top button